Novo Nordisk A/S Website

Novo Nordisk A/S

NYSE-NVO

Basic

  • Market Cap

    $577.24B

  • EV

    $576.78B

  • Shares Out

    4,461.33M

  • Revenue

    DKK 232.26B

  • Employees

    63,845

Margins

  • Gross

    84.6%

  • EBITDA

    47.28%

  • Operating

    44.77%

  • Pre-Tax

    45.07%

  • Net

    36.03%

  • FCF

    35.78%

Returns (5Yr Avg)

  • ROA

    30.33%

  • ROTA

    126.71%

  • ROE

    76.6%

  • ROCE

    79.16%

  • ROIC

    33.32%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $136.01

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    DKK 30.23B

  • Net Debt

    -DKK 3,224M

  • Debt/Equity

    0.25

  • EBIT/Interest

    191.86

Growth (CAGR)

  • Rev 3Yr

    22.31%

  • Rev 5Yr

    15.74%

  • Rev 10Yr

    10.76%

  • Dil EPS 3Yr

    27.4%

  • Dil EPS 5Yr

    18.51%

  • Dil EPS 10Yr

    14.82%

  • Rev Fwd 2Yr

    22%

  • EBITDA Fwd 2Yr

    23.96%

  • EPS Fwd 2Yr

    22.34%

  • EPS LT Growth Est

    6.99%

Dividends

  • Yield

    —

  • Payout

    50.35%

  • DPS

    DKK 9.4

  • DPS Growth 3Yr

    27.36%

  • DPS Growth 5Yr

    18.2%

  • DPS Growth 10Yr

    15.37%

  • DPS Growth Fwd 2Yr

    20.01%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Metric
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23

Total Revenues

122,021

126,946

140,800

176,954

232,261

Total Revenues % Chg.

9.1%

4%

10.9%

25.7%

31.3%

Cost of Goods Sold, Total

20,088

20,932

23,658

28,448

35,765

Gross Profit

101,933

106,014

117,142

148,506

196,496

Selling General & Admin Expenses, Total

35,830

36,886

41,058

50,684

61,598

R&D Expenses

14,220

15,462

17,199

23,287

31,029

Other Operating Expenses

-600

-460

-332

-1,034

-119

Other Operating Expenses, Total

49,450

51,888

57,925

72,937

92,508

Operating Income

52,483

54,126

59,217

75,569

103,988

Interest Expense, Total

-220

-390

-289

-378

-542

Interest And Investment Income

65

337

231

239

1,069

Net Interest Expenses

-155

-53

-58

-139

527

Income (Loss) On Equity Invest.

—

-137

149

-24

-189

81

Currency Exchange Gains (Loss)

-3,212

-747

344

-4,651

1,652

Other Non Operating Income (Expenses)

-281

-150

-122

-181

-197

EBT, Excl. Unusual Items

48,698

53,325

59,357

70,409

106,051

Gain (Loss) On Sale Of Investments

-145

-195

296

-587

37

Gain (Loss) On Sale Of Assets

—

—

—

—

—

—

—

—

—

Asset Writedown

—

—

—

—

—

—

—

-573

-760

-1,414

Other Unusual Items

—

—

—

—

—

—

—

—

—

EBT, Incl. Unusual Items

48,553

53,130

59,080

69,062

104,674

Income Tax Expense

9,602

10,992

11,323

13,537

20,991

Earnings From Continuing Operations

38,951

42,138

47,757

55,525

83,683

Net Income

38,951

42,138

47,757

55,525

83,683

Net Income to Common Incl Extra Items

38,951

42,138

47,757

55,525

83,683

Net Income to Common Excl. Extra Items

38,951

42,138

47,757

55,525

83,683

Total Shares Outstanding

4,704

4,625

4,557.8

4,500.7

4,458.3

Weighted Avg. Shares Outstanding

4,748.6

4,667.8

4,593.2

4,530.6

4,482.8

Weighted Avg. Shares Outstanding Dil

4,757.4

4,680

4,606.2

4,544.6

4,494.8

EPS

8.2

9

10.4

12.3

18.7

EPS Diluted

8.2

9

10.4

12.2

18.6

EBITDA

56,310

58,565

63,770

80,875

109,813

Effective Tax Rate

19.8%

20.7%

19.2%

19.6%

20.1%